{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:08:03Z","timestamp":1792681683409,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12325-024-02843-8","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T08:51:57Z","timestamp":1714553517000},"page":"2500-2518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase\u00a03 PaTHway Trial"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct04701203","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lars","family":"Rejnmark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira O.","family":"Gosmanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores M.","family":"Shoback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Kohlmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishaela R.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Makara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ominsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Ukena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-5289","authenticated-orcid":false,"given":"Aimee D.","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"issue":"6","key":"2843_CR1","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1210\/jc.2015-3909","volume":"101","author":"DM Shoback","year":"2016","unstructured":"Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab. 2016;101(6):2300\u201312.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2843_CR2","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1002\/jbmr.4691","volume":"37","author":"AA Khan","year":"2022","unstructured":"Khan AA, Bilezikian JP, Brandi ML, et al. Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop. J Bone Miner Res. 2022;37(12):2568\u201385.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2843_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11154-020-09613-1","volume":"22","author":"EO Gosmanova","year":"2021","unstructured":"Gosmanova EO, Houillier P, Rejnmark L, Marelli C, Bilezikian JP. Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review: renal disease in chronic hypoparathyroidism. Rev Endocr Metab Disord. 2021;22(2):297\u2013316.","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2843_CR4","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s12325-021-01658-1","volume":"38","author":"EO Gosmanova","year":"2021","unstructured":"Gosmanova EO, Chen K, Rejnmark L, et al. Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: a retrospective cohort study. Adv Ther. 2021;38(4):1876\u201388.","journal-title":"Adv Ther"},{"key":"2843_CR5","doi-asserted-by":"publisher","first-page":"6078881","DOI":"10.1155\/2022\/6078881","volume":"2022","author":"EO Gosmanova","year":"2022","unstructured":"Gosmanova EO, Ayodele O, Chen K, et al. Association of calcium and phosphate levels with incident chronic kidney disease in patients with hypoparathyroidism: a retrospective case\u2013control study. Int J Endocrinol. 2022;2022:6078881.","journal-title":"Int J Endocrinol"},{"issue":"8","key":"2843_CR6","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/jbmr.4016","volume":"35","author":"DB Karpf","year":"2020","unstructured":"Karpf DB, Pihl S, Mourya S, et al. A randomized double-blind placebo-controlled first-in-human phase\u00a01 trial of TransCon PTH in healthy adults. J Bone Miner Res. 2020;35(8):1430\u201340.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2843_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jbmr.4726","volume":"38","author":"AA Khan","year":"2023","unstructured":"Khan AA, Rubin MR, Schwarz P, et al. Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase\u00a03 PaTHway Trial. J Bone Miner Res. 2023;38(1):14\u201325.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2843_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354.","journal-title":"Ann Intern Med"},{"issue":"7","key":"2843_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14326","volume":"35","author":"TJ Mayne","year":"2021","unstructured":"Mayne TJ, Nordyke RJ, Schold JD, Weir MR, Mohan S. Defining a minimal clinically meaningful difference in 12-month estimated glomerular filtration rate for clinical trials in deceased donor kidney transplantation. Clin Transplant. 2021;35(7):e14326.","journal-title":"Clin Transplant"},{"issue":"7","key":"2843_CR10","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1681\/ASN.2015040341","volume":"27","author":"E Ku","year":"2016","unstructured":"Ku E, Xie D, Shlipak M, et al. Change in measured GFR versus eGFR and CKD outcomes. J Am Soc Nephrol. 2016;27(7):2196\u2013204.","journal-title":"J Am Soc Nephrol"},{"key":"2843_CR11","doi-asserted-by":"crossref","unstructured":"Noori W, Inguva S, Sibley CT, Chirikov V, Smith A. Clinical and economic burden of postsurgical chronic hypoparathyroidism: a US medicare retrospective analysis. Poster Presentation at ENDO 2023; June 15\u201328, 2023; Chicago, Illinois.","DOI":"10.1210\/jendso\/bvad114.529"},{"issue":"3","key":"2843_CR12","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-18-0609","volume":"180","author":"AA Khan","year":"2019","unstructured":"Khan AA, Koch CA, Van Uum S, et al. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. Eur J Endocrinol. 2019;180(3):P1\u2013P22.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2843_CR13","doi-asserted-by":"publisher","first-page":"e3557","DOI":"10.1210\/clinem\/dgaa490","volume":"105","author":"KS Chen","year":"2020","unstructured":"Chen KS, Gosmanova EO, Curhan GC, et al. Five-year estimated glomerular filtration rate in patients with hypoparathyroidism treated with and without rhPTH(1\u201384). J Clin Endocrinol Metab. 2020;105(10):e3557\u201365.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2843_CR14","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1007\/s12325-022-02292-1","volume":"39","author":"O Ayodele","year":"2022","unstructured":"Ayodele O, Rejnmark L, Mu F, et al. Five-year estimated glomerular filtration rate in adults with chronic hypoparathyroidism treated with rhPTH(1\u201384): a retrospective cohort study. Adv Ther. 2022;39(11):5013\u201324.","journal-title":"Adv Ther"},{"issue":"4","key":"2843_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/cen.14813","volume":"98","author":"L Rejnmark","year":"2023","unstructured":"Rejnmark L, Ayodele O, Lax A, Mu F, Swallow E, Gosmanova EO. The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1\u201384): a retrospective cohort study. Clin Endocrinol (Oxf). 2023;98(4):496\u2013504.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2843_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/978-1-4684-4259-5_64","volume":"151","author":"M Rambausek","year":"1982","unstructured":"Rambausek M, Ritz E, Rascher W, et al. Vascular effects of parathyroid hormone (PTH). Adv Exp Med Biol. 1982;151:619\u201332.","journal-title":"Adv Exp Med Biol"},{"issue":"3\u20134","key":"2843_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0014-2999(84)90452-7","volume":"97","author":"HH Wang","year":"1984","unstructured":"Wang HH, Drugge ED, Yen YC, Blumenthal MR, Pang PK. Effects of synthetic parathyroid hormone on hemodynamics and regional blood flows. Eur J Pharmacol. 1984;97(3\u20134):209\u201315.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2843_CR18","first-page":"988","volume":"75","author":"FD Grant","year":"1992","unstructured":"Grant FD, Mandel SJ, Brown EM, Williams GH, Seely EW. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J Clin Endocrinol Metab. 1992;75(4):988\u201392.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2843_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","volume":"1","author":"M Mannstadt","year":"2013","unstructured":"Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase\u00a03 study. Lancet Diabetes Endocrinol. 2013;1(4):275\u201383.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2843_CR20","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1210\/jc.2019-01010","volume":"104","author":"M Mannstadt","year":"2019","unstructured":"Mannstadt M, Clarke BL, Bilezikian JP, et al. Safety and efficacy of 5\u00a0years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism. J Clin Endocrinol Metab. 2019;104(11):5136\u201347.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2843_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.clinthera.2014.04.001","volume":"36","author":"BL Clarke","year":"2014","unstructured":"Clarke BL, Kay Berg J, Fox J, Cyran JA, Lagast H. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1\u201384) in patients with hypoparathyroidism: an open-label, single-dose, phase\u00a0I study. Clin Ther. 2014;36(5):722\u201336.","journal-title":"Clin Ther"},{"key":"2843_CR22","doi-asserted-by":"crossref","unstructured":"Clarke B, Khan A, Rubin M, et al. Long-term efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the open-label extension of the phase\u00a03 PaTHway trial. Presented at: Endocrine Society Annual Meeting; June 15\u201318, 2023; Chicago, IL.","DOI":"10.1210\/jendso\/bvad114.563"},{"key":"2843_CR23","unstructured":"Vokes T, Rejnmark L, Schwarz P, et al. The PaTH forward trial: efficacy and safety of TransCon PTH through week\u00a084 for adults with hypoparathyroidism. Oral Presentation at ENDO 2022; June 11\u201314, 2022; Atlanta, Georgia."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02843-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T09:24:55Z","timestamp":1716888295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02843-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2843"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02843-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"30 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lars Rejnmark: Research funding from Takeda, Kyowa Kirin International, Ascendis, and Calcilytix; honoraria from Calcilytix Therapeutics; advisory board for Takeda and Amolyt. Elvira Gosmanova: Honoraria from Novo Nordisk and Takeda; advisory board role for Ascendis Pharma and Takeda; travel, accommodations, and expenses from Ascendis Pharma; industry-sponsored grants from AstraZeneca, AbbVie, and Kowa Research Institute. Aliya Khan: Research funding and\/or industry grants from Amolyt, Ascendis, Chugai, Radius, and Takeda; honoraria from and advisory board member for Amgen, Alexion, Ascendis, and Takeda; travel, accommodations, and expenses from Ascendis; consulting role for Amgen, Alexion, Amolyt, and Ascendis; speakers bureau participation for Amgen. Noriko Makita: Research funding from Kyowa Kirin. Yasuo Imanishi: speakers bureau for Kyowa Kirin Co., Ltd and Daiichi Sankyo Co., Ltd. Yasuhiro Takeuchi: Honoraria from Chugai Pharmaceutical Co. Ltd; consulting fee from Teijin Pharma; speakers bureau for Amgen Japan. Stuart Sprague: Research funding from Amgen, Amylot, Ascendis, Ardelyx, Frensinius, and OPKO and consultant Amgen, Ardelyx, Bayer, Fresenius, Horizon, OPKO, and Shire. Dolores Shoback: Research\/salary funding from Bone Health Tech; research funding from Ascendis. Lynn Kohlmeier: Research funding from Amolyt and Ascendis; speakers bureau, honoraria from Amgen, Radius, and Ascendis; advisory board, consultant for Radius, Alexion, and Ascendis. Mishaela Rubin: Study investigator for Takeda, Ascendis, Amolyt, and Calcilytix; advisory board for Ascendis, speakers bureau for Ascendis; consulting for MBX. Andrea Palermo: Consultant for Theramex, Bruno Farmaceutici, Amgen; research funding from Amgen, Shire, Ascendis; speakers bureau UCB, Amgen; industry grant from Amgen. Peter Schwarz: Stock ownership Novo Nordisk, Genmab. Claudia Gagnon: Advisory board member for Novo Nordisk; honoraria from Amgen; industry grants from Ascendis, Shire, and Takeda. Elena Tsourdi: Honoraria from Amgen, UCB, Takeda, Kyowa Kirin, and Ascendis; advisory board member for Amgen and UCB. Carol Zhao, Michael Makara, Michael Ominsky, Bryant Lai, Jenny Ukena, Christopher Sibley, and Aimee Shu are full-time employees of Ascendis Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol was reviewed by the appropriate institutional review boards and independent ethics committees (Supplementary Material Table\u00a0\n                      \n                      ). The trial was designed by the sponsor and authors and conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines as described in the International Conference on Harmonization Guideline E6. All participants provided signed informed consent before treatment initiation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}